Summary
Stryker Corporation's 2023 10-K filing highlights robust top-line growth driven by strong unit volume increases across its MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The company reported net sales of $20.5 billion, an increase of 11.1% year-over-year, with constant currency growth at 11.6%. This growth was supported by product innovation and market expansion, including the acquisition of Cerus Endovascular. Profitability showed improvement, with operating income rising significantly, reflecting effective cost management and favorable pricing, though offset by increased manufacturing and supply chain costs. Stryker continues to prioritize its capital allocation strategy, investing in acquisitions, returning capital to shareholders through dividends, and engaging in share repurchases. The company maintains a strong liquidity position, with substantial cash from operations and access to credit markets. Key operational risks identified include supply chain disruptions, inflationary pressures, pricing pressures within the healthcare industry, and regulatory compliance. The company's robust risk management framework, including cybersecurity, is actively overseen by management and the Board of Directors.
Financial Highlights
51 data points| Revenue | $20.50B |
| Cost of Revenue | $7.44B |
| Gross Profit | $13.06B |
| R&D Expenses | $1.39B |
| SG&A Expenses | $7.11B |
| Operating Expenses | $9.17B |
| Operating Income | $3.89B |
| Interest Expense | $356.00M |
| Net Income | $3.17B |
| EPS (Basic) | $8.34 |
| EPS (Diluted) | $8.25 |
| Shares Outstanding (Basic) | 379.60M |
| Shares Outstanding (Diluted) | 383.70M |
Key Highlights
- 1Stryker reported net sales of $20.5 billion for 2023, an 11.1% increase year-over-year, with organic constant currency growth of 11.6%.
- 2Both the MedSurg and Neurotechnology segment (+11.5%) and the Orthopaedics and Spine segment (+10.5%) demonstrated strong sales growth.
- 3Gross profit margin improved to 63.7% in 2023 from 62.8% in 2022, driven by pricing and volume, despite increased manufacturing and supply chain costs.
- 4The company successfully completed the acquisition of Cerus Endovascular, strengthening its Neurovascular portfolio.
- 5Operating income increased significantly by 36.8% to $3.9 billion, with operating margin improving to 19.0% from 15.4%.
- 6Stryker returned approximately $1.1 billion in dividends to shareholders and maintained a strong liquidity position with $3.1 billion in cash, cash equivalents, and marketable securities.
- 7Key risks highlighted include ongoing inflationary pressures, supply chain disruptions, pricing regulations in international markets (e.g., China's VBP programs), and cybersecurity threats.